ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Samsung BioLogics will spend $730 million to build a biologics facility at its site in Songdo, South Korea. The new plant, the company’s third, will feature 180,000 L of fermentation capacity for mammalian-cell-culture-based biologics. Samsung BioLogics employs 1,000 people and expects its headcount will rise to 1,800 in 2018 when the plant comes on-line. The contract manufacturer is majority-owned by Samsung Electronics and other Samsung firms.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter